Epithalon (Epitalon)

Epithalon (also spelled Epitalon in some scientific literature and commercial contexts) is a synthetic tetrapeptide consisting of four amino acids in the sequence alanine-glutamic acid-aspartic acid-glycine (Ala-Glu-Asp-Gly, abbreviated AEDG). ^(1,2) The peptide has a molecular formula of C14H22N4O9. It belongs to a class of compounds known as peptide bioregulators, short regulatory peptides that influence gene expression and cellular function at very low concentrations. ^(1,2)

Epithalon was first identified as the putative active component of Epithalamin, a polypeptide preparation extracted from bovine pineal glands. ^(1,2) The research was pioneered by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, part of the North-Western Division of the Russian Academy of Medical Sciences, beginning in the 1980s. ^(2,3) Khavinson’s work established the field of peptide bioregulation, demonstrating that short peptides derived from organ-specific extracts could restore function in aging tissues. The synthetic tetrapeptide Epithalon was created to replicate the geroprotective (anti-aging) effects of the crude pineal extract Epithalamin in a defined, reproducible molecular form. ^(1,2)

The name “Epithalon” derives from “Epithalamin” by shortening the suffix. The alternative spelling “Epitalon” appears in many international publications and is used interchangeably in the scientific literature. A third variant, “Epithalone,” also appears occasionally. All three names refer to the identical AEDG tetrapeptide. ⁽¹⁾ Epithalamin itself is sometimes confused with Epithalon. Still, they are distinct: Epithalamin is the crude pineal gland extract containing multiple peptides, while Epithalon is the specific synthetic tetrapeptide identified as the primary active component. ⁽²⁾

The central research interest in Epithalon is its ability to activate telomerase, the ribonucleoprotein enzyme responsible for adding telomeric DNA repeats (TTAGGG in humans) to the ends of chromosomes. ^(3,4) Telomere shortening with each cell division is a fundamental mechanism of cellular aging (also spelled aging), and telomerase activation is one of the most actively investigated strategies for extending cellular lifespan and health span. ⁽³⁾ In human clinical studies conducted in Russia, both Epithalon and Epithalamin significantly increased telomere lengths in the blood cells of elderly patients aged 60-65 and 75-80, with comparable efficacy between the synthetic peptide and the natural extract. ^(2,5)

Epithalon is not FDA-approved for any therapeutic indication. In September 2023, the FDA classified Epithalon (listed as Epitalon) as a Category 2 bulk drug substance, preventing compounding pharmacies in the United States from preparing it for patients. ⁽⁶⁾ In February 2026, a potential reclassification was announced by the U.S. Department of Health and Human Services, though no formal FDA policy change had been published as of March 2026. ⁽⁷⁾ Outside the United States, Epithalon has not been approved by the MHRA (UK) or the TGA (Australia) for any therapeutic indication. It is available as a research peptide for laboratory and investigational use. Healius supplies Epithalon as a lyophilized (also referred to as lyophilized) powder in 10mg and 50mg vials, intended strictly for research applications.

Epithalon’s mechanism of action centers on the activation of telomerase, specifically by upregulating the human telomerase reverse transcriptase (hTERT) catalytic subunit, the rate-limiting component of the telomerase enzyme complex. ^(3,4)

In most human somatic (non-reproductive) cells, telomerase is silenced after embryonic development, meaning that telomeres shorten with each cell division. ⁽³⁾ When telomeres reach a critically short length, the cell can no longer divide and enters a state of irreversible growth arrest known as replicative senescence. This phenomenon, called the Hayflick limit, is a fundamental mechanism of cellular aging. ⁽³⁾ Epithalon’s research significance lies in its demonstrated ability to reactivate telomerase in previously telomerase-negative somatic cells, thereby restoring the capacity for telomere maintenance and potentially extending the replicative lifespan of the cell. ^(3,4)

The 2003 study by Khavinson, Bondarev, and Butyugov, published in the Bulletin of Experimental Biology and Medicine, demonstrated that addition of Epithalon to telomerase-negative human fetal fibroblast cultures induced expression of the hTERT catalytic subunit, restored enzymatic telomerase activity, and produced measurable telomere elongation. ⁽³⁾ Untreated control fibroblasts lost their ability for mitosis after the 34th passage. At the same time, Epithalon-treated cells continued dividing beyond the 44th passage, directly demonstrating that the peptide enabled cells to surpass the Hayflick limit. ^(3,8)

A 2025 study from Brunel University London (Al-Dulaimi et al., published in Biogerontology) significantly expanded understanding of Epithalon’s mechanism. ⁽⁴⁾ This study confirmed telomerase upregulation in certain cell lines but also identified a second, previously unrecognized mechanism: activation of Alternative Lengthening of Telomeres (ALT). ⁽⁴⁾ ALT is a telomerase-independent pathway for telomere maintenance that operates through recombination-based mechanisms. The researchers speculated that Epithalon, which has been shown to bind the linker histone protein H1 (specifically H1.3 and H1.6), may trap proteins on DNA and induce ALT activity in cells in which telomerase is not the primary mechanism of telomere maintenance. ⁽⁴⁾ This dual mechanism (telomerase activation in some cell types, ALT activation in others) provides a more nuanced understanding of how Epithalon influences telomere biology across different cellular contexts.

Beyond telomerase, Epithalon interacts with DNA by preferentially binding methylated cytosine and specific DNA sequences (ATTTG and ATTTC), thereby influencing epigenetic regulation and gene expression. ^(1,2) The ATTTC sequence appears multiple times in the promoter region of the telomerase gene, providing a structural basis for how the peptide may directly modulate telomerase transcription. ⁽²⁾ Khavinson et al.  ⁽²⁰²⁰⁾, published in Molecules, demonstrated that Epithalon stimulates gene expression and protein synthesis during neurogenesis through what appears to be an epigenetic mechanism, further expanding the peptide’s known biological activities beyond telomere maintenance. ⁽⁹⁾

Epithalon benefits from one of the most extensive research histories of any longevity-focused peptide, spanning over three decades of investigation at the St. Petersburg Institute and, more recently, at Western research institutions. ^(1,2)

The human clinical evidence base, while primarily published in Russian-language journals, includes several notable findings. Both Epithalon and Epithalamin significantly increased telomere lengths in the blood cells of elderly patients in two age groups (60-65 and 75-80), with the synthetic peptide demonstrating comparable efficacy to the natural extract. ^(2,5) These studies represent rare human-level telomere intervention data and are frequently cited in the longevity research literature.

Epithalon and Epithalamin have both been shown to restore pineal melatonin secretion in aged monkeys and humans. ^(2,10) Melatonin is the primary circadian rhythm hormone, and its decline with age is associated with sleep disruption, reduced antioxidant capacity, and accelerated aging. The restoration of melatonin production provides a mechanistic link between Epithalon’s pineal gland origin and its observed effects on sleep quality and circadian regulation in aging research subjects. ⁽¹⁰⁾

A human clinical trial in patients with retinitis pigmentosa found that Epithalon produced a positive clinical effect in 90% of cases in the treated group, representing one of the earliest ophthalmological applications of the peptide. ⁽²⁾ Separate research demonstrated that Epithalon exerted a retinoprotective effect in Campbell rats at various ages, suggesting broader applications in age-related visual decline. ^(2,11)

In a clinical trial of patients with pulmonary tuberculosis, Epithalon did not correct pre-existing structural chromosomal aberrations associated with telomere degradation, but did exert a protective effect against the future development of additional chromosomal aberrations. ⁽²⁾ This finding is consistent with the peptide’s role in telomere maintenance: Epithalon may be more effective at preventing further telomere deterioration than at reversing existing damage.

The 2025 comprehensive review by Araj et al., published in the International Journal of Molecular Sciences (PMC11943447), provided an updated synthesis of all available Epithalon data, concluding that the compound demonstrates “significant geroprotective and neuroendocrine effects resulting from its antioxidant, neuroprotective, and antimutagenic activities.” ⁽¹⁾ The review emphasised that Epithalon’s effects arise from both specific mechanisms (telomerase activation, histone binding) and nonspecific mechanisms (antioxidant enzyme upregulation, free radical scavenging). ⁽¹⁾

Animal studies have provided important data on Epithalon’s effects on lifespan, cancer incidence, and age-related pathology, though the results are not uniform and should be interpreted with appropriate caution. ^(1,2)

Khavinson et al.  ⁽²⁰⁰⁰⁾ demonstrated that Epithalon increased lifespan in Drosophila melanogaster (fruit flies), providing initial evidence of geroprotective effects in a genetically tractable model organism. ^(2,12) In rodent studies, treatment of aging mice with Epithalon significantly reduced the incidence of chromosomal aberrations in both wild-type mice and mice with an accelerated aging phenotype, consistent with the telomere-protective mechanism observed in cell culture. ⁽²⁾

The anti-cancer data for Epithalon is particularly noteworthy. In an experiment on one-year-old female mice of the C3H/He inbred strain, Epithalon reduced the number of spontaneous tumors (also spelled tumors) and the number of metastases in mice that did develop tumors. ⁽²⁾ This oncostatic (tumor-suppressing) and anti-metastatic profile is significant because it directly addresses the most common safety concern about telomerase activation: whether increasing telomerase activity could promote cancer. The Epithalon data suggest that the peptide may have selective effects, activating telomerase in normal somatic cells while exerting anti-tumor effects in cancer models. ^(1,2)

A 2025 study by Ullah et al. demonstrated that Epithalon enhanced mitochondrial health in bovine cumulus cells and oocytes, reduced intracellular reactive oxygen species levels, and upregulated expression of PGC-1alpha, Sirt-1, tFAM, and BCL2. ⁽¹⁾ This research extended Epithalon’s known biological activity beyond telomere maintenance into mitochondrial function, suggesting overlap with the metabolic mechanisms of exercise and caloric restriction, both established longevity interventions.

Antioxidant effects have been documented in aging rat studies, in which Epithalon increased the activities of three key antioxidant enzymes: superoxide dismutase, glutathione peroxidase, and glutathione-S-transferase. ⁽²⁾ This antioxidant upregulation provides a mechanism for cellular protection independent of telomere elongation and may contribute to the peptide’s broader geroprotective effects.

It is important to note that the animal lifespan literature is not uniform. A frequently cited 2003 mouse study found no significant increase in mean lifespan, though changes in late survivors and maximum lifespan were observed. ⁽¹³⁾ These mixed results underscore that Epithalon’s effects on organismal longevity are more complex than its cell-level telomerase activation would suggest, and that large-scale, independently replicated animal lifespan studies remain an important gap in the evidence base.

Epithalon and Pinealon are both short regulatory peptides developed within the Khavinson research tradition at the St. Petersburg Institute of Bioregulation and Gerontology. Still, they have distinct origins, mechanisms, and research applications. ^(1,14)

Epithalon (AEDG) is a tetrapeptide derived from the pineal gland extract Epithalamin. Its primary mechanism involves telomerase activation and telomere maintenance, with secondary effects on melatonin restoration, upregulation of antioxidant enzymes, and epigenetic regulation. ^(1,3) The research profile centers on cellular aging, telomere biology, longevity, and circadian rhythm restoration.

Pinealon is a tripeptide (Glu-Asp-Arg, or EDR) that was also identified from pineal gland research but has a distinct neuroprotective and cognitive focus. ⁽¹⁴⁾ Pinealon’s research profile centers on neuroprotection, cognitive function support, and regulation of gene expression in nervous tissue. While both peptides originate from pineal gland research, they target different downstream pathways: Epithalon targets telomerase and systemic aging mechanisms, while Pinealon targets neuronal survival and cognitive function.

For researchers studying longevity from a telomere maintenance perspective, Epithalon is the more relevant compound. For researchers studying neuroprotection and age-related cognitive decline, Pinealon may be more appropriate. Some research protocols combine both peptides to address aging from complementary angles: telomere protection (Epithalon) and neuroprotection (Pinealon). Healius offers both compounds for independent or combination protocol design.

N-Acetyl Epithalon Amidate is a modified variant of standard Epithalon featuring N-terminal acetylation and C-terminal amidation, the same dual modification strategy applied to variants of other research peptides, such as Semax and Selank. ⁽¹⁵⁾

The acetylation protects the N-terminus from aminopeptidase degradation, while the amidation protects the C-terminus from carboxypeptidase activity. Together, these modifications increase the peptide’s resistance to enzymatic degradation, resulting in improved stability and potentially extended biological activity compared to standard Epithalon. ⁽¹⁵⁾ The modified variant is frequently marketed as a nasal spray formulation, reflecting the enhanced stability needed for intranasal delivery.

However, all published clinical trial data, including the Khavinson telomerase studies, the human telomere length studies, and the animal lifespan research, used standard Epithalon (AEDG) rather than the modified variant. N-Acetyl Epithalon Amidate has less published research support, and its pharmacokinetic advantages over standard Epithalon have not been validated in controlled human studies.

Healius supplies standard Epithalon, the form with the most extensive published research base and over 30 years of documented investigation. Researchers requiring modified variants should note the reduced evidence base relative to the standard tetrapeptide.

1. Araj SK, Brzezik J, Madra-Gackowska K, Szeleszczuk L. Overview of Epitalon: Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences. 2025;26(6):2691. PMC11943447.

2. Wikipedia. Epitalon. Comprehensive source overview of synthesis, mechanism, animal studies, human clinical data, telomerase activation, melatonin restoration, and cancer research. Updated January 2026.

3. Khavinson VK, Bondarev IE, Butyugov AA. Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells. Bulletin of Experimental Biology and Medicine. 2003;135(6):590-592. PubMed: 12937682.

4. Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. Brunel University London. PMC12411320.

5. Human clinical studies: Epithalon and Epithalamin significantly increased telomere lengths in blood cells of patients aged 60-65 and 75-80, and referenced in Khavinson’s clinical publications and Wikipedia synthesis.

6. FDA. Safety Risks Associated with Certain Bulk Drug Substances Nominated for Use in Compounding. September 2023. Epitalon is classified as a Category 2 bulk drug substance.

7. RFK Jr. / HHS announcement regarding potential reclassification of Category 2 peptides. February 27, 2026. Formal FDA policy change not yet published as of March 2026.

8. Khavinson VK, et al. Peptide Promotes Overcoming of the Division Limit in Human Somatic Cells. Bulletin of Experimental Biology and Medicine. 2004. (Hayflick limit surpassed: 44th passage vs 34th in controls.)

9. Khavinson V, Diomede F, Mironova E, et al. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules. 2020;25(3):609.

10. Epithalon and Epithalamin restore melatonin secretion in aged monkeys and humans. Referenced in Anisimov & Khavinson 2010 (Biogerontology) and multiple pineal peptide reviews.

11. Khavinson VK, Razumovsky MI, Trofimova SV, Razumovskaya AM. Retinoprotective Effect of Epithalon in Campbell Rats of Various Ages. Bulletin of Experimental Biology and Medicine. 2003; 135:495-498.

12. Khavinson VK, Izmaylov DM, Obukhova LK, Malinin VV. Effect of Epitalon on the Lifespan Increase in Drosophila melanogaster. Mechanisms of Aging and Development. 2000.

13. PeptidesDirect. Epitalon Peptide: Telomere Research and Anti-Aging Science. Critical analysis noting mixed results on animal lifespan. July 2025.

14. Pinealon (EDR): tripeptide from Khavinson research tradition targeting neuroprotection, cognitive function, and neuronal gene expression. Distinct from Epithalon’s telomerase/longevity focus.

15. N-Acetyl Epithalon Amidate: modified variant with N-terminal acetylation and C-terminal amidation for enhanced enzymatic resistance. Less published evidence than the standard Epithalon.

16. WADA Prohibited List 2026. Section S0: Non-Approved Substances—any pharmacological substance with no current governmental regulatory approval for human therapeutic use.

17. Anisimov VN, Khavinson VK. Peptide Bioregulation of Aging: Results and Prospects. Biogerontology. 2010;11(2):139-149.

This product is sold strictly for laboratory and research use only. It is not intended for human or animal consumption. It is not a dietary supplement, food, drug, or cosmetic. It is not intended to diagnose, treat, cure, or prevent any disease or condition. The buyer assumes all responsibility for the lawful use of this product in accordance with all applicable local, state, national, and international laws and regulations. By purchasing this product, the buyer confirms that they are a qualified researcher or are purchasing on behalf of a research institution.